Design and synthesis of potent, selective, and orally bioavailable tetrasubstituted imidazole inhibitors of p38 mitogen-activated protein kinase.

Novel potent and selective diarylimidazole inhibitors of p38 MAP (mitogen-activated protein) kinase are described which have activity in both cell-based assays of tumor necrosis factor-alpha (TNF-alpha) release and an animal model of rheumatoid arthritis. The SAR leading to the development of selectivity against c-Raf and JNK2alpha1 kinases is presented, with key features being substitution of the 4-aryl ring with m-trifluoromethyl and substitution of the 5-heteroaryl ring with a 2-amino substituent. Cell-based activity was significantly enhanced by incorporation of a 4-piperidinyl moiety at the 2-position of the imidazole which also enhanced aqueous solubility. In general, oral bioavailability of this class of compounds was found to be poor unless the imidazole was methylated on nitrogen. This work led to identification of 48, a potent (p38 MAP kinase inhibition IC50 0.24 nM) and selective p38 MAP kinase inhibitor which inhibits lipopolysaccharide-stimulated release of TNF-alpha from human blood with an IC50 2.2 nM, shows good oral bioavailability in rat and rhesus monkey, and demonstrates significant improvement in measures of disease progression in a rat adjuvant-induced arthritis model.

[1]  S. Luell,et al.  Therapeutic administration of a selective inhibitor of nitric oxide synthase does not ameliorate the chronic inflammation and tissue damage associated with adjuvant-induced arthritis in rats. , 1998, The Journal of pharmacology and experimental therapeutics.

[2]  E. A. O'neill,et al.  Kinetic mechanism for p38 MAP kinase. , 1997, Biochemistry.

[3]  K. Rossen,et al.  Synthesis of the orally active spiroindoline-based growth hormone secretagogue, MK-677 , 1997 .

[4]  E. Tindall,et al.  Treatment of rheumatoid arthritis with a recombinant human tumor necrosis factor receptor (p75)-Fc fusion protein. , 1997, The New England journal of medicine.

[5]  D E Griswold,et al.  Pharmacological profile of SB 203580, a selective inhibitor of cytokine suppressive binding protein/p38 kinase, in animal models of arthritis, bone resorption, endotoxin shock and immune function. , 1996, The Journal of pharmacology and experimental therapeutics.

[6]  I. Kawasaki,et al.  Total Synthesis of Nortopsentins A-D, Marine Alkaloids , 1996 .

[7]  Jiahuai Han,et al.  Characterization of the Structure and Function of a Novel MAP Kinase Kinase (MKK6) (*) , 1996, The Journal of Biological Chemistry.

[8]  J. Lin,et al.  Potent and selective inactivation of human liver microsomal cytochrome P-450 isoforms by L-754,394, an investigational human immune deficiency virus protease inhibitor. , 1995, The Journal of pharmacology and experimental therapeutics.

[9]  Philip R. Cohen,et al.  SB 203580 is a specific inhibitor of a MAP kinase homologue which is stimulated by cellular stresses and interleukin‐1 , 1995, FEBS letters.

[10]  R. SanMartin,et al.  A new general method for the synthesis of 4-hydroxylated 3-aryltetrahydroisoquinolines , 1995 .

[11]  G. Kingsley,et al.  The therapeutic effects of an engineered human anti-tumour necrosis factor alpha antibody (CDP571) in rheumatoid arthritis. , 1995, British journal of rheumatology.

[12]  Jiahuai Han,et al.  Pro-inflammatory Cytokines and Environmental Stress Cause p38 Mitogen-activated Protein Kinase Activation by Dual Phosphorylation on Tyrosine and Threonine (*) , 1995, The Journal of Biological Chemistry.

[13]  T. Choshi,et al.  The Total Synthesis of the Marine Antitumor Grossularine-2 , 1995 .

[14]  Jerry L. Adams,et al.  A protein kinase involved in the regulation of inflammatory cytokine biosynthesis , 1994, Nature.

[15]  J. Woody,et al.  Randomised double-blind comparison of chimeric monoclonal antibody to tumour necrosis factor α (cA2) versus placebo in rheumatoid arthritis , 1994, The Lancet.

[16]  J. Woody,et al.  Repeated therapy with monoclonal antibody to tumour necrosis factor α (cA2) in patients with rheumatoid arthritis , 1994, The Lancet.

[17]  J. Lin,et al.  Physiological disposition of L-663,581, a partial agonist of the benzodiazepine receptor, in laboratory animals. , 1994, Drug metabolism and disposition: the biological fate of chemicals.

[18]  G. Leclerc,et al.  A Convenient Synthesis of cis‐4‐(Sulfomethyl)‐piperidine‐2‐carboxylic Acid: NMR Assignment. , 1993 .

[19]  G. Leclerc,et al.  A convenient synthesis of cis‐4‐(sulfomethyl)‐piperidine‐2‐carboxylic acid: NMR assignment , 1993 .

[20]  K. Tracey,et al.  Tumor necrosis factor, other cytokines and disease. , 1993, Annual review of cell biology.

[21]  C. Dinarello,et al.  Inflammatory cytokines: interleukin-1 and tumor necrosis factor as effector molecules in autoimmune diseases , 1991, Current Biology.

[22]  L. Strekowski,,et al.  Highly regioselective bromination reactions of polymethylpyrimidines , 1991 .

[23]  A. Hamon,et al.  Cephalosporins with C-7-isocyanide dihalides : useful synthons for the introduction of amino heterocycles at C-7 - new routes to the synthesis of amino imidazoles , 1989 .

[24]  K. Undheim,et al.  Stannylation reaction and cross-couplings in pyrimidines , 1989 .

[25]  B. Lipshutz,et al.  Ti(III)-Mediated reductions of N-hydroxy imidazoles to 1-protio-2,4(5)-disubstituted derivatives , 1984 .

[26]  K. Hayes.  I‐Hydroxyimidazole 3‐oxide and some 2‐substituted derivatives , 1974 .

[27]  J. Gannon,et al.  Nitrosation of .alpha.,.beta.-unsaturated oximes. IV. Synthesis and structure of 3,4-diazacyclopentadienone derivatives , 1969 .